Source link : https://www.newshealth.biz/health-news/small-benefit-persistent-toxic-risk-with-adjuvant-anthracycline-in-breast-cancer/
Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk of heart failure, a randomized trial showed. Patients who received epirubicin and cyclophosphamide prior to docetaxel (EC-D) had a 21% reduction in the hazard for distant disease-free […]
Author : News Health
Publish date : 2024-11-19 22:15:26
Copyright for syndicated content belongs to the linked Source.
Categories